M&A Deal Summary |
|
|---|---|
| Date | 2010-12-20 |
| Target | EMD/Merck Crop BioScience |
| Sector | Life Science |
| Buyer(s) | Novozymes |
| Sellers(s) | Merck |
| Deal Type | Divestiture |
| Deal Value | 275M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1925 |
| Sector | Life Science |
| Employees | 6,641 |
| Revenue | 15.0B DKK (2021) |
Novozymes produces a wide range of industrial enzymes and microorganisms, providing innovative answers to some of the world’s most pressing challenges. Company innovative biological solutions improve industrial manufacturing processes by saving energy, water and raw materials, while reducing waste and emissions, and helping make everyday products more sustainable. The planet’s population is growing, consuming more and putting a strain on natural resources. Novozymes is helping the world address these challenges. Novozymes was founded in 1925 and is based in Bagsvaerd, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 10 |
| Sector (Life Science) | 3 of 6 |
| Type (Divestiture) | 2 of 2 |
| State (Wisconsin) | 1 of 1 |
| Country (United States) | 2 of 4 |
| Year (2010) | 2 of 2 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-08-11 |
Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos LTDA
Quatro Barras, Brazil Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos LTDA is a microorganisms and supplier of sustainable solutions to the agriculture industry. Turfal’s inoculant products are microbes that stimulate the growth of crops, especially soybean, by fixating nitrogen. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-11-28 |
Natural Industries
Houston, Texas, United States Natural Industries manufactures patented organic microorganisms used for plant protection and health by horticulture and agriculture professionals as well as retail lawn & garden enthusiasts. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1668 |
| Sector | Diversified |
| Employees | 64,011 |
| Revenue | 22.2B EUR (2022) |
Merck is a science and technology company in healthcare, life science and performance materials. Merck develops technologies that improve and enhance life from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Merck was founded in 1668 and is based in Darmstadt, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 7 |
| Sector (Life Science) | 4 of 4 |
| Type (Divestiture) | 5 of 7 |
| State (Wisconsin) | 1 of 1 |
| Country (United States) | 2 of 2 |
| Year (2010) | 2 of 2 |
| Size (of disclosed) | 5 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-28 |
Thermamex
London, United Kingdom Theramex is a global specialty pharmaceutical company dedicated to women and their health. The Company markets a broad range of branded and branded generic products across 50 countries around the world. The portfolio, which is dedicated to women's health, focuses on contraception, fertility, menopause and osteoporosis and includes key brands such as Ovaleap®, Zoely®, Seasonique®, Actonel®, Estreva® and Lutenyl®. Thermamex is based in London, United Kingdom. |
Sell | €265M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-01-05 |
Beijing Skywing Technology
Beijing, China Beijing Skywing Technology Co., Ltd., is a supplier of cell-culture media products, related technical services and bioreactors for the Chinese biopharmaceutical industry. |
Buy | CN¥120M |
